These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21965780)

  • 1. Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer.
    Czejka M; Kiss A; Koessner C; Terkola R; Ettlinger D; Schueller J
    Anticancer Res; 2011 Oct; 31(10):3573-8. PubMed ID: 21965780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
    van Riel JM; van Groeningen CJ; Kedde MA; Gall H; Leisink JM; Gruia G; Pinedo HM; van der Vijgh WJ; Giaccone G
    Clin Cancer Res; 2002 Feb; 8(2):405-12. PubMed ID: 11839656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer.
    Czejka M; Schueller J; Hauer K; Ostermann E
    Anticancer Res; 2005; 25(4):2985-90. PubMed ID: 16080556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
    Shitara K; Munakata M; Kudo T; Kasai M; Muto O; Okada R; Mitobe S; Ishiguro A; Sakuraba H; Ikami I; Sakata Y
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2033-7. PubMed ID: 17197748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
    Horita Y; Yamada Y; Hirashima Y; Kato K; Nakajima T; Hamaguchi T; Shimada Y
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):467-71. PubMed ID: 19554330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Gonen M; Stockman J; Blumgart L; Sperber D; Hummer A; Fong Y
    J Clin Oncol; 2003 Sep; 21(17):3303-9. PubMed ID: 12947066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
    Shimonov M; Hayat H; Chaitchik S; Brener J; Schachter P; Czerniak A
    Chemotherapy; 2005 May; 51(2-3):111-5. PubMed ID: 15886466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.
    Czejka M; Gruenberger B; Kiss A; Farkouh A; Schueller J
    Anticancer Res; 2010 Jun; 30(6):2355-60. PubMed ID: 20651393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
    Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
    J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion of irinotecan and EmboCept
    Kauffels A; Kitzmüller M; Gruber A; Nowack H; Bohnenberger H; Spitzner M; Kuthning A; Sprenger T; Czejka M; Ghadimi M; Sperling J
    Clin Exp Metastasis; 2019 Feb; 36(1):57-66. PubMed ID: 30680598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
    Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
    Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sigmoid colon cancer with multiple liver metastasis (H3) effectively treated with CPT-11 and DSM (degradable starch microsphere) HAI therapy and intensive high dosage 5-FU HAI therapy--a case report].
    Yukawa M; Ishikawa H; Nakayama T; Oshima S; Katsumoto Y; Furukawa J; Sue F; Inoue M
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1763-7. PubMed ID: 11708029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y
    J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
    Yamaguchi T; Matsumoto H; Yasutome M; Mori T; Takahashi K
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):629-35. PubMed ID: 20495917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
    Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
    Eur J Clin Pharmacol; 2019 Apr; 75(4):529-542. PubMed ID: 30610273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transarterial chemoembolization with irinotecan (CPT-11) and degradable starch microspheres (DSM) in patients with liver metastases from colorectal cancer].
    Tsuchiya M; Watanabe M; Otsuka Y; Yamazaki K; Tamura A; Ishii J; Koike J; Funahashi K; Teramoto T; Kaneko H
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):2038-40. PubMed ID: 18219891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.